Monitoring CD27+memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study

被引：55

作者：

Cohen, M. ^{[1
]}

Romero, G. ^{[1
]}

Bas, J. ^{[2
]}

Ticchioni, M. ^{[3
]}

Rosenthal, M. ^{[3
]}

Lacroix, R. ^{[4
]}

Brunet, C. ^{[4
]}

Rico, A. ^{[2
]}

Pelletier, J. ^{[2
]}

Audoin, B. ^{[2
]}

Lebrun, C. ^{[1
]}

机构：

[1] Hop Pasteur 2, Dept Neurol, Nice, France

[2] Aix Marseille Univ, AP HM, Hop Timone, Serv Neurol,Pole Neurosci Clin, F-13005 Marseille, France

[3] Hop Archet, Dept Immunol, Nice, France

[4] CHU La Concept, AP HM, Hematol & Vasc Biol Dept, Marseille, France

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 2017年 / 373卷

关键词：

Rituximab; NMO; Immunology; Health care costs; Monoclonal antibodies; Biomarkers; EXTENSIVE BRAIN-LESIONS; NATALIZUMAB; INTERFERON; THERAPY; IGG; NMO;

D O I：

10.1016/j.jns.2017.01.025

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Rituximab (RTX) is increasingly used in the treatment of neuromyelitis optica spectrum disorder (NMO-SD). Administration regimen is not consensual as there is no reliable biomarker of RTX efficacy. In most cases, after induction, RTX is administered systematically every 6 months. Objective: To assess efficacy and safety of a maintenance regimen based on CD19 + CD27 + memory B-cell (mBc) detection. Methods: We conducted a study in two French centers, including patients with NMO-SD who received an induction therapy with RTX. We compared the number of administered infusions, relapses and EDSS depending on two maintenance schemes (S1: administration of 1 g RTX infusion every 6 months or S2: a scheme based on regular mBc detection. 1 g RTX was administered if mBc was >0.05%) Results: 40 patients were included (mean age: 40.2 years, F/M sex ratio: 5/1). Aquaporin-4 antibodies were positive in 75% patients. Under S1 regimen, all patients received 2 infusions per year, whereas under S2, they received 1.62 infusion per year. The mean interval between infusions under S2 was 7.4 months, without decrease of clinical efficacy. Conclusion: In our study, mBc-based administration of RTX allowed personalizing treatment administration and in several cases to lower the cumulative dose without loss of efficacy. (C) 2017 Elsevier B.V. All rights reserved.

引用

页码：335 / 338

页数：4

共 20 条

[1]

Annovazzi P., 2016, J NEUROL, P1

[2]

Ayzenberg I., 2016, J NEUROL, P1

[3]

Cabre P., 2012, J NEUROL NEUROSURG P

[4] Efficacy of rituximab in refractory neuromyelitis optica [J].